Mapping the road to biologics in psoriasis and psoriatic arthritis: A nationwide drug utilization study
Open Access
- 7 August 2023
- journal article
- research article
- Published by Wiley in JEADV Clinical Practice
- Vol. 2 (4) , 857-863
Abstract
Background: Limited research has been conducted on whether advances in novel biologics and biosimilars have improved the treatment journey preceding biologics.Objectives: To map the overall treatment journey preceding the initiation of first biologic therapy in patients with psoriasis (PsO) and psoriatic arthritis (PsA), as well as the changes over time.Methods: Using Danish nationwide registries, we included all patients treated with a first‐time biologic (2010–2018) for either PsO or PsA and reported the medical treatment journey. We used Sankey diagrams to illustrate the flow of treatment series.Results: The study included 2082 patients with PsO (62.5% male) and 1831 patients with PsA (42.3% male). Before biologics, 49.5% treated for PsO and 36.8% treated for PsA received ≥2 type therapies and 59.3% with PsO and 25.5% with PsA received ≥3 treatment series. Median time from first systemic therapy to a biologic was 3.9 years (Q1–Q3, 1.3–4.1) for PsO and 2.1 years (Q1–Q3, 0.6–5.8) for PsA. The majority of patients with PsO (1174 [56.4%]) received multiple treatment series with the same drug, while almost a third of patients with PsA (572 [31.2%]) did the same. Twelve percent of patients with PsO and 6.4% of patients with PsA repeated treatment with a drug they had already stopped for an alternative treatment.Conclusions: Although most patients are adequately managed, our findings suggest the possibility of a yet too long and complicated treatment journey before starting biologics.Keywords
This publication has 11 references indexed in Scilit:
- Impact of Psoriatic Disease on Quality of Life: Interim Results of a Global SurveyDermatology and Therapy, 2022
- Overview of Sankey flow diagrams: Focusing on symptom trajectories in older adults with advanced cancerJournal of Geriatric Oncology, 2022
- Choice of Systemic Drugs for the Management of Moderate-to-severe Psoriasis: A Cross-country Comparison Based on National Health Insurance DataActa Dermato-Venereologica, 2021
- EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 updateAnnals of the Rheumatic Diseases, 2020
- The Danish health care system and epidemiological research: from health care contacts to database recordsClinical Epidemiology, 2019
- The journey of adult psoriasis patients towards biologics: past and present ‐ Results from the BioCAPTURE registryJournal of the European Academy of Dermatology and Venereology, 2017
- An evolution in switching therapy for psoriasis patients who fail to meet treatment goalsDermatologic Therapy, 2015
- Diagnostic delay of more than 6 months contributes to poor radiographic and functional outcome in psoriatic arthritisAnnals of the Rheumatic Diseases, 2015
- Epidemiological and clinical characteristics of psoriatic arthritis in northern NorwayScandinavian Journal of Rheumatology, 2009
- The Burden of Psoriasis Is Not Determined by Disease Severity OnlyJournal of Investigative Dermatology Symposium Proceedings, 2004